A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of INCB 99280 in Combination with Ipilimumab for Patients with Advanced Kidney Cancer
Background: Ipilimumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Ipilimumab targets the immune checkpoint molecule CTLA-4 and allows the body to increase the...
A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer
Background: Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®). Pembrolizumab (Keytruda®) is an immunotherapy drug that is...
A Study of Belzutifan + Pembrolizumab versus Pembrolizumab Alone for Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. Belzutifan (Welireg®) is a drug that is...
A Study of Combination Durvalamab + Savolitinib versus Sunitinib or Durvalamab Alone in Patients with Papillary Kidney Cancer
Background: Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a...
A Study of Different Immune and Targeted Therapies for 1st Line Treatment of Kidney Cancer (Substudy 03A)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI)...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...
A Study on Preventing Toxicity in Kidney Cancer Patients Using Fecal Transplantation (PERFORM)
Background: The term "microbiome" refers to all of the microorganisms (including bacteria, fungi, and other living things) that live inside and on the surface of the human body. There is growing evidence that suggests the microbiome plays a large role in our overall health and wellbeing....
Stereotactic Body Radiation Therapy (SBRT) with Ipilimumab and Nivolumab for Advanced Kidney Cancer (CYTOSHRINK)
Background: Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues. The drugs used in...